VolitionRX Ltd (VNRX)

Jun 16, 2025

VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock By Investing.com - Investing.com India

Jun 16, 2025

Jun 16, 2025

VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock - Investing.com

Jun 16, 2025

Jun 12, 2025

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure - MarketScreener

Jun 12, 2025

Jun 11, 2025

VolitionRx (NYSE:VNRX) Rating Increased to Strong-Buy at Jones Trading - Defense World

Jun 11, 2025

Jun 10, 2025

VolitionRX (VNRX) Coverage Initiated with a 'Buy' Rating by Jones Trading | VNRX Stock News - GuruFocus

Jun 10, 2025

Jun 10, 2025

JonesTrading Initiates Coverage on VolitionRx Limited With Buy Rating, $3 Price Target - marketscreener.com

Jun 10, 2025

Jun 09, 2025

Jones Trading initiates VolitionRX with Buy, sets $3 target By Investing.com - Investing.com India

Jun 09, 2025

Jun 09, 2025

VolitionRx (VNRX) Receives Buy Rating with Promising Price Targe - GuruFocus

Jun 09, 2025

Jun 09, 2025

VolitionRx initiated with a Buy at JonesResearch - TipRanks

Jun 09, 2025

Jun 09, 2025

VolitionRx (VNRX) Receives Buy Rating with Promising Price Target | VNRX Stock News - GuruFocus

Jun 09, 2025

Jun 04, 2025

Director Makes Bold Move with Major VolitionRX Stock Purchase - TipRanks

Jun 04, 2025

Jun 04, 2025

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties - Yahoo Finance

Jun 04, 2025

Jun 04, 2025

VolitionRx director Guy Innes buys $10,772 in common stock By Investing.com - Investing.com South Africa

Jun 04, 2025

Jun 04, 2025

VolitionRx director Guy Innes buys $10,772 in common stock - Investing.com

Jun 04, 2025

May 27, 2025

VNRX: Management's key financial goal for 2025 is to be cash neutral on a full year basis. - Research Tree

May 27, 2025

May 27, 2025

VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applicati - Yahoo Finance

May 27, 2025

May 20, 2025

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 20, 2025

May 19, 2025

VolitionRX Ltd. Earnings Call Reveals Promising Growth - TipRanks

May 19, 2025

May 19, 2025

VolitionRX shares hold as Benchmark maintains rating - Investing.com Australia

May 19, 2025

May 19, 2025

VNRX stock touches 52-week low at $0.42 amid market challenges - Investing.com Canada

May 19, 2025

May 19, 2025

VolitionRX shares hold as Benchmark maintains rating By Investing.com - Investing.com India

May 19, 2025

May 19, 2025

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats - Yahoo Finance

May 19, 2025

May 19, 2025

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats By Investing.com - Investing.com Canada

May 19, 2025

May 17, 2025

VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones - Yahoo Finance

May 17, 2025

May 17, 2025

VolitionRx Reports Strong Q1 2025 Performance - TipRanks

May 17, 2025

May 16, 2025

VolitionRX (VNRX) Sees Revenue Growth and Cost Reduction in Q1 2 - GuruFocus

May 16, 2025

May 16, 2025

Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast By Investing.com - Investing.com Nigeria

May 16, 2025

May 16, 2025

Transcript : VolitionRx Limited, Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com

May 16, 2025

May 16, 2025

Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast - Investing.com

May 16, 2025

May 16, 2025

Volitionrx Ltd earnings missed by $0.02, revenue fell short of estimates - Investing.com UK

May 16, 2025

May 16, 2025

VolitionRX: Q1 Earnings Snapshot - CT Insider

May 16, 2025

May 16, 2025

VolitionRx Q1 2025 Earnings Call Transcript - MarketBeat

May 16, 2025

May 15, 2025

Volitionrx Ltd earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa

May 15, 2025

May 15, 2025

VolitionRx reports Q1 revenue $0.25M, consensus $1.08M - TipRanks

May 15, 2025

May 15, 2025

Volition (VNRX) Targets Diagnostic Market Expansion with Nu.Q Platform | VNRX Stock News - GuruFocus

May 15, 2025

May 15, 2025

VolitionRX Ltd Reports Q1 2025 Revenue of $0.25 Million, Missing - GuruFocus

May 15, 2025

May 15, 2025

VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus

May 15, 2025

May 12, 2025

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update - Yahoo Finance

May 12, 2025

May 10, 2025

VolitionRx (VNRX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 10, 2025

May 09, 2025

VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock - Barchart.com

May 09, 2025

May 07, 2025

VolitionRx Updates Progress Of Nu.Q NETs Test Adoption - marketscreener.com

May 07, 2025

May 07, 2025

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption - Yahoo Finance

May 07, 2025

May 07, 2025

StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World

May 07, 2025

Apr 29, 2025

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets - Yahoo Finance

Apr 29, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Apr 23, 2025

VolitionRx enters new sales agreement, terminates old one - Investing.com Australia

Apr 23, 2025

Apr 22, 2025

VolitionRx enters new sales agreement, terminates old one By Investing.com - Investing.com South Africa

Apr 22, 2025